Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis.

被引：0
|
作者：
Dong, Wei [1 ]
Zhang, Songyan [1 ]
Huo, Zhuoni [1 ]
Lu, Junrong [1 ]
Liu, Haishi [1 ]
Wang, Ping [1 ]
Zhang, Yubao [1 ]
机构：
[1] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16160
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Lenvatinib plus hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma.
    Yamamoto, Makoto
    Terashima, Takeshi
    Yamashita, Tatsuya
    Yanagi, Masahiro
    Nakagawa, Hidetoshi
    Seki, Akihiro
    Nio, Kouki
    Arai, Kuniaki
    Toyama, Tadashi
    Yamashita, Taro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 496 - 496
  • [32] Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis
    Li, Yangyang
    Liu, Wendao
    Chen, Junwei
    Chen, Yongxin
    Guo, Jiandong
    Pang, Huajin
    Zhang, Wentao
    An, Chao
    Li, Chengzhi
    CANCER MEDICINE, 2024, 13 (01):
  • [33] Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
    Zhao, Shu
    Zhou, Minhang
    Wang, Peng
    Yang, Jing
    Zhang, Dong
    Yin, Fan
    Song, Peng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [34] Efficacy of Lenvatinib Combined with PD-1 Inhibitor versus Sorafenib and PD-1 Inhibitor with or Without TACE for Hepatocellular Carcinoma with
    Duan, Wen-Bin
    Wang, Xiao-Hui
    Zhang, Guo-Can
    He, Zhuo
    Li, Shao-Qiang
    Zhou, Jie
    IMMUNOTARGETS AND THERAPY, 2024, 13 : 247 - 258
  • [35] Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: Analysis of 160 patients
    Ando, E
    Tanaka, M
    Yamashita, F
    Kuromatsu, R
    Takada, A
    Sumie, S
    Fukumori, K
    Yano, Y
    Kumashiro, R
    Sata, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 88 - 89
  • [36] Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study
    Wang, Murong
    Zhou, Qunfang
    Li, Hui
    Liu, Mingyu
    Li, Ruixia
    Wang, Wei
    Wang, Xiaohui
    Huang, Jinhua
    Duan, Feng
    IMMUNOTARGETS AND THERAPY, 2024, 13 : 447 - 459
  • [37] Addition of Immune Checkpoint Inhibitor Showed Better Efficacy for Infiltrative Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy and Lenvatinib: A Multicenter Retrospective Study
    Wang, Wei
    Li, Ruixia
    Li, Hui
    Wang, Murong
    Wang, Juncheng
    Wang, Xiaohui
    Zhou, Qunfang
    IMMUNOTARGETS AND THERAPY, 2024, 13 : 399 - 412
  • [38] Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
    Tao, P.
    Wei, Y.
    Zhu, G.
    Zeng, Z.
    Lv, Z.
    Ma, J.
    Ye, X.
    Su, H.
    Xiao, K.
    Liao, J.
    Su, M.
    Yu, S.
    Long, L.
    Wang, J.
    Peng, N.
    Zhao, K.
    Han, C.
    Liao, X.
    Qin, W.
    Yang, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1547 - S1548
  • [39] Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
    Cai, Mingyue
    Huang, Wensou
    Huang, Jingjun
    Shi, Wenbo
    Guo, Yongjian
    Liang, Licong
    Zhou, Jingwen
    Lin, Liteng
    Cao, Bihui
    Chen, Ye
    Zhou, Juan
    Zhu, Kangshun
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [40] Neoadjuvant PD-1 blockade in combination with chemotherapy for patients with resectable esophageal squamous cell carcinoma
    Cheng Chao
    Yang Weixiong
    Chen Wenfang
    Yeung, Sau-Ching Jim
    Xing Xiangbin
    Wang Xiaoyan
    Bao Yong
    Feng Shiting
    Peng Fang
    Liu Zhenguo
    Zeng Bo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345